"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 2 | 1 | 3 |
| 2007 | 2 | 1 | 3 |
| 2008 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy. Front Immunol. 2023; 14:1155778.
-
Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody. J Clin Invest. 2022 12 01; 132(23).
-
Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives. Expert Rev Clin Immunol. 2022 Dec; 18(12):1217-1237.
-
Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 107(5):85-87.
-
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30; 388(10043):488-97.
-
Marta Batus on the New Direct-to-Consumer Advertising for Nivolumab, and Its Impact on Oncology Practice. Oncology (Williston Park). 2016 Jun; 30(6):506, 523.
-
Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthritis Cartilage. 2015 Aug; 23(8):1254-66.
-
Sclerostin antibody increases bone volume and enhances implant fixation in a rat model. J Bone Joint Surg Am. 2012 Sep 19; 94(18):1670-80.
-
Cognitive performance correlates with cortical isopeptide immunoreactivity as well as Alzheimer type pathology. J Alzheimers Dis. 2008 Feb; 13(1):53-66.
-
Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008 Feb; 35(2):201-5.